Ind-Swift Laboratories Ltd. (INDSWFTLAB) AI Stock Analysis

• Market Cap: ₹11.22B
• Dividend Yield: N/A
• Average Volume (3M): 7.30K
• Price to Earnings (P/E): 18.9
• Beta (1Y): 1.27
• Revenue Growth: -37.70%
• EPS Growth: -19.79%
• Country: IN
• Employees: 47
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.17
• Shares Outstanding: 81,611,560
• 10 Day Avg. Volume: 7,859
• 30 Day Avg. Volume: 7,299
• PEG Ratio: -0.04
• Price to Book (P/B): 0.46
• Price to Sales (P/S): 0.96
• P/FCF Ratio: -5.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: ₹145.00 ▲(59.87% Upside)
• Action: Reiterated Date: 03/06/26
• Date: Action: Reiterated 03/06/26

The score is primarily supported by strong sales growth and a very low-leverage balance sheet, but is held back by negative operating and free cash flow. Technicals are moderately constructive with an established uptrend, while valuation appears mid-range without dividend support.

Positive Factors

Sustained Revenue Growth

Consistent double-digit top-line expansion reflects growing commercial traction across products and markets. Durable revenue momentum supports scale benefits, funds reinvestment in capacity or R&D, and provides a buffer to absorb cyclical margin pressure over the next 2–6 months.

Very Low Financial Leverage

Extremely low leverage gives the company strong financial flexibility to fund operations, capex, or opportunistic M&A without heavy interest burden. High ROE indicates efficient equity use, supporting long-term resilience and ability to withstand sector cyclicality.

Diversified Pharma Business Model

A multi-pronged revenue mix—APIs, finished formulations, exports and contract manufacturing—reduces concentration risk and leverages global generic demand. This structural diversification supports stable demand exposure and repeat contract revenue over medium-term horizons.

Negative Factors

Negative Operating & Free Cash Flow

Persistently negative operating and free cash flows undermine liquidity and cash-conversion. Even with low debt, weak cash generation restricts reinvestment, working-capital flexibility and may force reliance on external funding or equity issuance, risking dilution or higher financing costs.

Negative EBIT Margin

A negative EBIT margin signals core operating stress—costs or inefficiencies offsetting sales growth. Net income cushions may stem from non-operating items; this gap raises questions about profit quality and the sustainability of margins if underlying operational issues persist.

Earnings Contraction / Volatility

Declining EPS despite revenue growth indicates pressures on per-share profitability and potential one-off items or rising costs. Continued EPS contraction would erode investor confidence and may reflect inconsistent conversion of sales into durable shareholder returns.

Ind-Swift Laboratories Ltd. Business Overview & Revenue Model

Company Description

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.

How the Company Makes Money

Ind-Swift Laboratories Ltd. generates revenue through multiple key streams, primarily by selling its pharmaceutical products, which include APIs and finished formulations. The company benefits from a robust export business, supplying to various countries, thereby leveraging the global demand for affordable generic medications. Additionally, the company engages in contract manufacturing agreements with other pharmaceutical firms, providing them with production capabilities in exchange for financial compensation. Strategic partnerships with healthcare providers and distributors further enhance its market reach and profitability. Overall, the company’s revenue model is built on a combination of direct sales, exports, and contractual agreements, ensuring a steady flow of income.

Ind-Swift Laboratories Ltd. Financial Statement Overview

Summary

Strong revenue growth (25.63%) and a robust, low-leverage balance sheet (debt-to-equity 0.0178; ROE 44.97%) support the score, but it is materially constrained by negative operating and free cash flow in 2025, raising liquidity and cash-conversion concerns.

Income Statement

Ind-Swift Laboratories Ltd. has shown a strong revenue growth rate of 25.63% in the latest year, indicating robust sales expansion. However, the company experienced a significant drop in EBIT, resulting in a negative EBIT margin for 2025. Despite this, the net profit margin remains healthy due to a substantial net income, suggesting effective cost management or one-time gains.

Balance Sheet

The balance sheet reflects a strong equity position with a low debt-to-equity ratio of 0.0178 in 2025, indicating financial stability and low leverage. The return on equity is impressive at 44.97%, showcasing efficient use of equity to generate profits. The equity ratio is solid, suggesting a stable financial structure.

Cash Flow

Cash flow analysis reveals challenges, with negative operating and free cash flows in 2025, indicating potential liquidity issues. The free cash flow growth rate is negative, suggesting declining cash generation capabilities. The ratios of operating and free cash flow to net income are unfavorable, highlighting cash flow management concerns.

Breakdown	TTM	Jun 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	8.22B	5.62B	12.81B	12.07B	10.39B	8.91B
Gross Profit	4.19B	2.74B	4.13B	4.40B	4.10B	3.75B
EBITDA	3.05B	2.85B	7.82B	2.36B	2.35B	1.98B
Net Income	2.66B	2.50B	4.21B	475.97M	-21.49M	-31.47M
Balance Sheet
Total Assets	15.44B	14.38B	14.60B	18.24B	18.01B	18.18B
Cash, Cash Equivalents and Short-Term Investments	4.33B	4.82B	4.94B	231.54M	333.68M	116.01M
Total Debt	220.47M	408.41M	166.22M	8.62B	9.53B	10.05B
Total Liabilities	2.37B	2.65B	6.48B	11.42B	12.00B	12.15B
Stockholders Equity	13.07B	11.73B	9.36B	6.82B	6.01B	6.04B
Cash Flow
Free Cash Flow	-472.94M	-898.80M	-2.08B	1.82B	1.32B	1.31B
Operating Cash Flow	-202.50M	-254.74M	-1.63B	1.95B	1.50B	1.35B
Investing Cash Flow	-1.04B	-1.10B	-1.23B	-133.68M	47.72M	-101.72M
Financing Cash Flow	961.18M	692.05M	6.99B	-1.86B	-1.41B	-1.24B

Ind-Swift Laboratories Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 90.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDSWFTLAB, the sentiment is Neutral. The current price of 90.7 is below the 20-day moving average (MA) of 140.91, below the 50-day MA of 121.27, and below the 200-day MA of 106.22, indicating a neutral trend. The MACD of 4.63 indicates Positive momentum. The RSI at 52.73 is Neutral, neither overbought nor oversold. The STOCH value of 61.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:INDSWFTLAB.

Ind-Swift Laboratories Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	79 Outperform	₹11.95B	10.01	―	―	13.32%	218.38%
SAKAR	66 Neutral	₹11.39B	22.21	―	―	24.20%	55.01%
ZIMLAB	63 Neutral	₹3.25B	19.99	―	―	-5.82%	-59.22%
INDSWFTLAB	61 Neutral	₹11.22B	18.86	―	―	-37.70%	-19.79%
MEDICAMEQ	55 Neutral	₹3.72B	56.53	―	0.26%	-9.16%	49.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NECLIFE	46 Neutral	₹2.50B	7.63	―	―	-30.27%	-3470.06%

Ind-Swift Laboratories Ltd. Corporate Events

Ind-Swift Labs Retains ₹19.66 Crore as 6.5 Million Warrants Lapse

Ind-Swift Laboratories has announced that 6.5 million fully convertible warrants previously allotted on a preferential basis to Saral Incorporated VCC Sub Fund 1 have lapsed after the investor did not exercise the option to convert them into equity shares within the 18‑month window ending 28 February 2026. As a result, in line with SEBI regulations and the terms of the issue, the company has forfeited the upfront subscription amount of ₹19.66 crore, which had been paid as 25% of the issue price, effectively retaining this capital without issuing additional shares and thereby avoiding equity dilution for existing shareholders.

The lapse and forfeiture underscore the conditional nature of such preferential warrant issues, where investors’ decisions on conversion directly influence a company’s capital structure and fund-raising outcomes. For Ind-Swift, this event preserves its current share base while still benefiting from the forfeited funds, which may support its financial position, though it simultaneously means the company will not receive the remaining 75% of the warrant proceeds that would have come with a full conversion.

Ind-Swift Labs Files CARE Monitoring Report on Rs 314.6 Crore Preferential Issue

Ind-Swift Laboratories Ltd. has disclosed that CARE Ratings Limited, acting as the independent monitoring agency, has issued its report for the quarter ended 31 December 2025 on the company’s preferential issue of equity capital aggregating Rs 314.60 crore. The filing, made in compliance with SEBI regulations on capital issues and listing obligations, confirms that the monitoring process for the deployment and tracking of these preferential issue proceeds is ongoing, underscoring the company’s adherence to regulatory oversight and providing transparency for shareholders and market participants regarding the use of raised funds.

Ind-Swift Laboratories Closes Trading Window Ahead of Q3 FY2025 Results

Ind-Swift Laboratories Ltd. has announced the closure of its trading window for company securities from 1 January 2026 until 48 hours after the declaration of its unaudited standalone and consolidated financial results for the quarter ended 31 December 2025. The restriction, which applies to promoters, promoter group members, directors, key managerial personnel, designated persons, connected persons/insiders and their immediate relatives, is in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code of conduct, reinforcing compliance and governance standards aimed at preventing insider trading around key financial disclosures.

Ind-Swift Laboratories Completes Intra-Promoter Transmission of 232,057 Shares

Ind-Swift Laboratories Ltd. has informed the stock exchanges that 232,057 equity shares, originally held by the late promoter shareholder Neera Mehta, have now been transmitted to the joint demat account of her three legal heirs, all of whom are part of the company’s promoter and promoter group. The transfer, completed following regulatory approvals linked to the earlier amalgamation of Ind-Swift Limited with Ind-Swift Laboratories Limited and undertaken under an exemption for inter-se promoter transfers in the SEBI takeover regulations, results in no change to the aggregate shareholding of the promoters, signalling a purely intra-family realignment of ownership with no immediate implications for control or public shareholders.